AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04747171
Drug: intrathecal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intrathecal adjuvants to bupivacaine
Trial: NCT06493019
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemoradiation Pembrolizumab 200mg IV
Trial: NCT04842201
Drug: CM326
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous injection
Trial: NCT06493019
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 50 mg/m\^2 IV
Trial: NCT06493019
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 2 IV
Trial: NCT06493019
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance Pembrolizumab 400mg IV
Trial: NCT06561035
Drug: Opiate Sparing
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive medications in the Opiate Sparing arm for pain control.
Trial: NCT06696716
Drug: ONO-4059
RxNorm normalized name: ONO-4059 (free base)
DrugBank: Tirabrutinib (DB15227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirabrutinib is a Bruton's Tyrosine Kinase Inhibitor. Tirabrutinib will be administered orally at a dose of 80 mg once daily after a meal (breakfast, lunch, or dinner).
Trial: NCT06696716
Drug: ONO-4059 placebo
RxNorm normalized name: ONO-4059 (free base)
DrugBank: Tirabrutinib (DB15227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally once daily after a meal (breakfast, lunch, or dinner).
Trial: NCT04730206
Drug: Camostat
RxNorm normalized name: camostat
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 milligram tablets
Trial: NCT04730206
Drug: Molnupiravir
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 200 milligram tablets
Trial: NCT06043297
Drug: Apixaban 5MG
RxNorm normalized name: APIXABAN 5MG TAB
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each film-coated tablet contains 5 mg apixaban
Trial: NCT06043297
Drug: Eliquis 5 mg
RxNorm normalized name: Eliquis 5 MG Oral Tablet
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each film-coated tablet contains 5 mg apixaban
Trial: NCT05726253
Drug: Supportive Care + Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive oral amoxicillin for a standard course (7 days)
Trial: NCT06457581
Drug: serotonin reuptake inhibitor (SSRI)
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: serotonin reuptake inhibitor (SSRI)
Trial: NCT05025085
Drug: a PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody
Trial: NCT04880577
Drug: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]
RxNorm normalized name: TENOFOVIR ALAFENAMIDE FUMARATE 25 mg ORAL TABLET [VEMLIDY]
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The study is designed to add on TAF to anti-CD20 therapies
Trial: NCT05273827
Drug: neoadjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.
Trial: NCT05273827
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cis-platinum combined with paclitaxel or pemetrexed
Trial: NCT06655818
Drug: Belantamab Mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab Mafodotin will be administered.
Trial: NCT06655818
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab will be administered.
Trial: NCT05286060
Drug: GX-188E, GX-I7, Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 1200㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
Trial: NCT05286060
Drug: GX-188E, Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
Trial: NCT05286060
Drug: GX-188E, GX-I7, Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
Trial: NCT04510597
Drug: Active Comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID
Trial: NCT06063109
Drug: THP-00101 (Dapagliflozin) 10mg
RxNorm normalized name: THP-Adm
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B
Trial: NCT06063109
Drug: THP-00102 (Telmisartan) 80mg
RxNorm normalized name: THP-Adm
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A
Trial: NCT05600322
Drug: Hexaminolevulinate Hydrochloride
RxNorm normalized name: Hexaminolevulinate hydrochloride
DrugBank: Hexaminolevulinate (DB06261)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.
Trial: NCT05125211
Drug: GB001 recombinant peptide spray
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administrated oral spray
Trial: NCT04704323
Drug: CAP-100
DrugBank: CAP-1 (DB08027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP-100 (humanized antibody against C-C-chemokine receptor 7 \[CCR\]7)
Trial: NCT05946486
Drug: immunomodulatory treatment by rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days)
Trial: NCT04756037
Drug: Relugolix Combination Therapy
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive orally 1 fixed-dose combination tablet (relugolix 40 mg/E2 1 mg/NETA 0.5 mg) once daily.
Trial: NCT05133635
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.
Trial: NCT05133635
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.
Trial: NCT05393050
Drug: Colquhounia Root Tablet
RxNorm normalized name: kava root Oral Tablet
DrugBank: Kava (DB01322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colquhounia Root Tablet is a tripterygium preparation
Trial: NCT04916249
Drug: Tibetree Pain Relieving Plaster
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
Trial: NCT06196047
Drug: Ticagrelor 90 MG
RxNorm normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
Trial: NCT06196047
Drug: Cilostazol 100 MG
RxNorm normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efficacy and safety of 200 mg loading dose of cilostazol administered within 24 hours of first-ever ischemic stroke followed by 100 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
Trial: NCT04848597
Drug: Recombinant humanized anti-PD-1 monoclonal antibody injection
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg , once every 3 weeks
Trial: NCT05419869
Drug: ALTO-100 PO Tablet
RxNorm normalized name: Altoprev
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two tablets daily
Trial: NCT05854784
Drug: Afamelanotide 16 MG
RxNorm normalized name: afamelanotide 16 MG
DrugBank: Afamelanotide (DB04931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eligible patients will receive one dose of afamelanotide 16mg every 28 days (up to six doses), as a controlled-release formulation.
Trial: NCT05915442
Drug: Quemliclustat
RxNorm normalized name: Quemliclustat
DrugBank: Quemliclustat (DB19160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg IV once every two weeks
Trial: NCT05915442
Drug: Etrumadenant
RxNorm normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg orally (PO) once a day (QD)
Trial: NCT05915442
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg IV once every two weeks starting within 1 week of completing metastasis-directed SBRT
Trial: NCT04793295
Drug: MT-7117
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-7117
Trial: NCT04776447
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.~Other Name: ATC code: L01XA02
Trial: NCT05393466
Drug: BPI-361175
RxNorm normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.
Trial: NCT04776447
Drug: Placlitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.
Trial: NCT04776447
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. Atezolizumab targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.~Patients will receive 1200 mg of atezolizumab administered by IV infusion every 21 days (+/- 3 days) in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
Trial: NCT04890353
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Trial: NCT05626530
Drug: Letermovir
RxNorm normalized name: Letermovir
DrugBank: Letermovir (DB12070)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Open label 480 mg given daily for 60 days
Trial: NCT05747469
Drug: local anaesthetic injection
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous local anesthesia with 1% lidocaine without epinephrine is administered to the skin overlying the joint.
Trial: NCT06498128
Drug: Daridorexant
RxNorm normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing and treatment duration of QUVIVIQ as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
Trial: NCT05839509
Drug: GH001
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH001 administered via inhalation
Trial: NCT06006585
Drug: BI 771716
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 771716
Trial: NCT05327647
Drug: Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction intravesical BCG with bicalutamide 150 mg for 90 days
Trial: NCT05967286
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05967286
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05003245
Drug: Lucentis
RxNorm normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.05mL solution at a 4-week interval for intravitreal injection
Trial: NCT06446479
Drug: Dronabinol Pill
RxNorm normalized name: dronabinol Pill
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol 20 mg
Trial: NCT05173805
Drug: YL-15293
RxNorm normalized name: dibenzothiazol-2-yl disulfide
DrugBank: 2,2'-Dibenzothiazyl disulfide (DB14201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After enrollment, patients will receive oral YL-15293 twice a day until disease progression, unacceptable adverse events, concurrent diseases prevent further study treatment, the investigator decides to withdraw the patient, the patient withdraws consent, the patient is pregnant, or for administrative reasons. After treatment, the patients will continue to be followed up for 30 days. Patients who permanently stop the study treatment for reasons other than disease progression will be followed up for disease evaluation after treatment until the start of new anti-cancer treatment, withdrawal of consent, loss of follow-up, death or until the sponsor stops the study, whichever comes first.
Trial: NCT04742699
Drug: Lemborexant (LEM) 5 mg (Z-Drug-mono cohort)
RxNorm normalized name: lemborexant 5 MG
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Pretreatment phase: Continue pre-registration treatment (Z-drug monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for Z-Drug. Increasing LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment from the first treatment phase. Changing LEM dose is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition.
Trial: NCT06471868
Drug: IY-MIC
RxNorm normalized name: MIC
DrugBank: Methyl isocyanate (DB12765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betanechol 25mg
Trial: NCT04862767
Drug: TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
RxNorm normalized name: TASO-001
DrugBank: TASO-001 (DB17463)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 96 hour continuous infusion
Trial: NCT04742699
Drug: Lemborexant (LEM) 5 mg (SUV-mono cohort)
RxNorm normalized name: lemborexant 5 MG
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Pretreatment phase: Continue pre-registration treatment (SUV monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed.
Trial: NCT04854460
Drug: Stromectol (first dose)
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 tablet contain 6 mg Ivermecin
Trial: NCT04854460
Drug: Stromectol (second dose)
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 tablet contain 6 mg Ivermecin
Trial: NCT06157905
Drug: Oral Tofacitinib citrate
RxNorm normalized name: Tofacitinib Citrate
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tofacitinib citrate was initiated at 5 mg twice daily after ruling out contraindications
Trial: NCT05498857
Drug: Intramuscular ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia
Trial: NCT05105633
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
Trial: NCT05105633
Drug: Standard Care (which may include intravenous Alteplase)
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
Trial: NCT05265403
Drug: Commercially-available energy storage and return prosthetic foot
RxNorm normalized name: Fungi-Nail Toe and Foot
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient will walk in the Freedom Highlander, a commercially-available energy storage and return prosthetic foot. The foot will be sized based on the patient's foot size and weight.
Trial: NCT04742699
Drug: Lemborexant (LEM) 5 mg (SUV-combination cohort)
RxNorm normalized name: lemborexant 5 MG
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Pretreatment phase: Continue pre-registration treatment (SUV and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition.
Trial: NCT06062875
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
Trial: NCT05874414
Drug: GNS561 + Trametinib
RxNorm normalized name: Tramétinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg
Trial: NCT05525455
Drug: TT-816
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT-816 is a novel, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors
Trial: NCT05525455
Drug: A PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed death receptor-1 (PD 1)-blocking antibody
Trial: NCT00002220
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no